{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:12:05Z","timestamp":1779289925853,"version":"3.51.4"},"reference-count":32,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and objectives: The main objective of this study is to highlight the efficiency of different therapeutic means in patients with ankylosing spondylitis, resulting in the improvement of their quality of life. Materials and Methods: We conducted a randomized, longitudinal, controlled trial on 92 patients with ankylosing spondylitis over a period of 6 years. Disease activity was assessed using the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) score. The assessment of functional disabilities was performed using BASFI (Bath Ankylosing Spondylitis Functional Index). We assessed the quality of life using the HAQ questionnaire (Health Assessment Questionnaire). Based on the HAQ, we calculated the minimum number of patients to be treated for 52 weeks to prevent a decrease in the quality of life for at least one of them (the number needed to treat (NNT)). Results: For the combination therapy group, the result we obtained was 2, lower than the other therapies compared (the medication group and the group with physical exercise). We point out a correlation between the improvement of the functional status (BASFI) and the increase of the quality of life (HAQ), estimated as moderately high (0.8). The superiority of the effects of the combined treatment, in which we combined a nonsteroidal anti-inflammatory drug (etoricoxib) to the exercise program, is reflected by the model of the significant improvements (p &lt; 0.05) obtained for the functional status and quality of life scores (BASFI and HAQ). Conclusions: The nonsteroidal anti-inflammatory drugs, in our case, etoricoxib, facilitate the application of individualized exercise programs in patients with ankylosing spondylitis.<\/jats:p>","DOI":"10.3390\/medicina56060270","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T11:49:21Z","timestamp":1591012161000},"page":"270","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Non-Steroidal Anti-Inflammatory Drug Etoricoxib Facilitates the Application of Individualized Exercise Programs in Patients with Ankylosing Spondylitis"],"prefix":"10.3390","volume":"56","author":[{"given":"Iulia Rahela","family":"Marcu","sequence":"first","affiliation":[{"name":"Department of Physical and Rehabilitation Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Dop","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7398-5689","authenticated-orcid":false,"given":"Vlad","family":"Padureanu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan Adrian","family":"Niculescu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3095-736X","authenticated-orcid":false,"given":"Rodica","family":"Padureanu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Elena","family":"Niculescu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otilia Constantina","family":"Rogoveanu","sequence":"additional","affiliation":[{"name":"Department of Physical and Rehabilitation Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/MAJ.0b013e318294457f","article-title":"The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States","volume":"345","author":"Reveille","year":"2013","journal-title":"Am. J. Med. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/ar4228","article-title":"Microbes, the gut and ankylosing spondylitis","volume":"15","author":"Costello","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/BOR.0000000000000239","article-title":"Subclinical gut inflammation in ankylosing spondylitis","volume":"28","author":"Ciccia","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.38963","article-title":"Revisiting the arthritogenic peptide theory: Quantitative not qualitative changes in the peptide repertoire of HLA-B27 all types","volume":"67","author":"Schittenhelm","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3892\/mmr.2017.6248","article-title":"Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review)","volume":"15","author":"Chen","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.1038\/ncomms8146","article-title":"Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1","volume":"6","author":"Cortes","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_7","first-page":"1303","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"375","author":"Taurog","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jbspin.2018.01.006","article-title":"2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis","volume":"85","author":"Wendling","year":"2018","journal-title":"Joint Bone Spine."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American college of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_10","unstructured":"National Institute for Health and Care Excellence (2017). Spondyloarthritis in Over 16s: Diagnosis and Management, National Institute for Health and Care Excellence."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13075-016-1180-1","article-title":"Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis","volume":"18","author":"Levitova","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_13","first-page":"1740","article-title":"International spondyloarthritis interobserver reliability exercise\u2014The INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis","volume":"34","author":"Gladman","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_14","first-page":"1899","article-title":"The Cochrane review of physiotherapy interventions for ankylosing spondylitis","volume":"32","author":"Dagfinrud","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1177\/0091270004268129","article-title":"The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity","volume":"44","author":"Agrawal","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"ref_16","first-page":"573","article-title":"Characterization of etoricoxib, a novel, selective COX-2 inhibitor","volume":"43","author":"Dallob","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/0091270003257219","article-title":"Pharmacokinetics of etoricoxib in patients with hepatic impairment","volume":"43","author":"Agrawal","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/ard.2004.029611","article-title":"The efficacy of cyclooxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis","volume":"64","author":"Gossec","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/ard.2010.138883","article-title":"ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF\u03b1 inhibitors","volume":"70","author":"Pedersen","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1526-5900(03)00633-3","article-title":"Etoricoxib Protocol 042 Study Group. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: Improvement in pain and disability\u2014A randomized, placebo-controlled, 3-month trial","volume":"4","author":"Birbara","year":"2003","journal-title":"J. Pain."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/annrheumdis-2012-203055","article-title":"Efficacy of oral prednisolone in active ankylosing spondylitis: Results of a double-blind, randomised, placebo-controlled short-term trial","volume":"73","author":"Haibel","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3111\/13696998.2012.692341","article-title":"Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents","volume":"15","author":"Gao","year":"2012","journal-title":"J. Med. Econ."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3899\/jrheum.170166","article-title":"Response to tumor necrosis factor inhibition in male and female patients with ankylosing spondylitis: Data from a swiss cohort","volume":"45","author":"Hebeisen","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2\u2005years on radiographic progression of the spine: Results from a randomized multicenter trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","unstructured":"Hernandez-Garduno, A., Vazquez-Leduc, A., and Querol-Vinagre, J.V. (2005, January 8\u201311). Clinical evaluation following treatment with etoricoxib (60, 90 and 120mg once a day) in patients with acute low back pain: A cohort, open, non-randomized, multicenter study. Proceedings of the Annual Meeting of the European League Against Rheumatism, Vienna, Austria. SAT0362."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/03009740410005728","article-title":"Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: A 3 month, randomized, controlled trial","volume":"33","author":"Pallay","year":"2004","journal-title":"Scand. J. Rheumatol."},{"key":"ref_28","unstructured":"Jansen, J.P., Hunsche, E., and Choi, E. (2005, January 8\u201311). Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK [abstact]. Proceedings of the Annual Meeting of the European League Against Rheumatism, Vienna, Austria. FRI0475."},{"key":"ref_29","unstructured":"Jarret, S.J., Mc Gonagle, D., and Marzo-Ortega, H. (2004, January 16\u201321). Etoricoxib reduces the need for biologic therapy in ankylosing spondylitis (AS) but has no effect on magnetic resonance imaging. Proceedings of the American College of Rheumatology 68th Annual Scientific Meeting, San Antonio, TX, USA. Results from an open study [abstract]."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2519\/jospt.2005.35.6.356","article-title":"Pharmacology in rehabilitation: Nonsteroidal anti-inflammatory agents","volume":"35","author":"Biederman","year":"2005","journal-title":"J. Orthop. Sports Phys. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00007256-200333030-00002","article-title":"Use of nonsteriodal anti-inflammatory drugs following exercise reduced muscle injury","volume":"33","author":"Lanier","year":"2003","journal-title":"Sports Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.20985","article-title":"Evaluation of the Efficacy of Etoricoxib in Ankylosing Spondylitis: Results of a Fifty-Two-Week, Randomized, Controlled Study","volume":"52","author":"Baraf","year":"2005","journal-title":"Arthr. Rheum."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/6\/270\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:33:57Z","timestamp":1760175237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/6\/270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["medicina56060270"],"URL":"https:\/\/doi.org\/10.3390\/medicina56060270","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]}}}